Can this pill tame the nausea from popular Weight-Loss shots?

NCT ID NCT06500429

Completed Symptom relief Sponsor: Neurogastrx, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested whether an oral drug called NG101 can reduce gastrointestinal side effects (like nausea and vomiting) caused by GLP-1 weight-loss medications such as semaglutide. 120 healthy adults with a BMI between 22 and 35 took either NG101 or a placebo for five days, and received a single injection of semaglutide on day two. Researchers measured how long and how severe stomach-related side effects lasted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NG101 (metopimazine mesylate)
What this could lead to: If it works, NG101 could become a pill that helps people tolerate common GLP-1 drugs by reducing nausea, vomiting, and other stomach issues.
What could go wrong: This is a small, early proof-of-concept study in healthy volunteers, not patients. The drug may not work as well in real-world use or could have its own side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY OVERWEIGHT AND OBESITY

Contacts and locations

Locations

Celerion

Tempe, Arizona, 85283, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.